Biopsy Guidance System

Biopsy Guidance System Market Outlook

The global biopsy guidance system market is projected to reach approximately USD 5.8 billion by 2035, growing at a CAGR of 7.5% during the forecast period from 2025 to 2035. This growth is primarily driven by technological advancements in imaging modalities that enhance the accuracy and reliability of biopsies, alongside an increasing prevalence of cancer globally, which necessitates early and accurate diagnosis. The growing demand for minimally invasive procedures and an uptick in the elderly population, who are more susceptible to various types of cancers, are additional factors fueling market expansion. Furthermore, the rise in healthcare expenditure and improved reimbursement scenarios for biopsy procedures are expected to provide a favorable environment for market growth. Continuous research and development activities aimed at enhancing biopsy techniques and safety profiles are also anticipated to significantly contribute to the market dynamics.

Growth Factor of the Market

The biopsy guidance system market is experiencing significant growth due to multiple converging factors. Firstly, the alarming increase in cancer incidence rates worldwide necessitates efficient diagnostic tools, thereby pushing the demand for advanced biopsy guidance systems. Moreover, the advancement in imaging technologies, such as MRI and CT scans, which aid in precise localization of lesions, has proven to be a game-changer in biopsy procedures. Additionally, the trend towards minimally invasive surgeries has gained traction, as these methods are associated with quicker recovery times and reduced postoperative complications, further augmenting market growth. The rise of targeted therapies and personalized medicine, contingent on accurate histopathological diagnosis, also drives the need for reliable biopsy systems. Furthermore, ongoing investments and funding in healthcare infrastructure by governments and private entities create an encouraging landscape for the adoption of innovative biopsy solutions.

Key Highlights of the Market

• Significant growth in the market driven by rising cancer incidence and advancements in imaging technologies.
• Minimally invasive procedures are becoming increasingly preferred due to lower complications and quicker recovery times.
• Technological innovations in biopsy guidance systems are enhancing precision and patient outcomes.
• Increased investments in healthcare infrastructure support the adoption of advanced biopsy technologies.
• Growing awareness about early cancer detection fuels demand for biopsy procedures globally.

By Product Type

Needle Biopsy:

Needle biopsy is one of the most common types of biopsy guidance systems favored for its minimally invasive nature. It involves the use of a thin needle to extract tissue samples from suspicious lesions for pathological examination. The increasing preference for needle biopsies can be attributed to their reduced recovery times, minimal scarring, and lower complication rates compared to traditional surgical methods. As needle biopsy techniques continue to evolve, incorporating advanced imaging technologies for enhanced accuracy, they are likely to dominate the biopsy guidance system market. Furthermore, needle biopsies can be performed under local anesthesia, making them more accessible in outpatient settings, thus contributing to their growing adoption.

Surgical Biopsy:

Surgical biopsy, which involves the excision of a larger portion of tissue for examination, remains a vital segment of the biopsy guidance system market. This method is typically employed when a larger sample is required for accurate diagnosis, especially in cases where the lesion is of considerable size or complexity. Moreover, surgical biopsies can provide comprehensive diagnostic information due to the larger amount of tissue obtained. The segment is expected to grow as surgical techniques improve, particularly with advancements in robotic-assisted surgeries that enhance precision and reduce recovery times. Nonetheless, the more invasive nature of surgical biopsies compared to needle biopsies may limit their use in certain patient populations, especially in those that favor minimally invasive options.

By Application

Breast Biopsy:

Breast biopsy is a critical application in the field of oncology, particularly for the early detection and diagnosis of breast cancer. With rising awareness and screening efforts, the demand for breast biopsies is increasing, driving the growth of biopsy guidance systems. The integration of imaging modalities such as ultrasound and MRI into breast biopsy procedures enhances the accuracy of targeting suspicious lesions. Moreover, innovations in vacuum-assisted biopsy technologies are making the procedures faster and more efficient, further encouraging their adoption. As breast cancer remains one of the leading causes of cancer-related morbidity among women, the continued focus on improving biopsy techniques for breast tissue analysis is expected to significantly bolster this market segment.

Prostate Biopsy:

The prostate biopsy segment is witnessing growth due to the increasing prevalence of prostate cancer among men globally. Transrectal ultrasound-guided biopsy has become a standard practice for prostate cancer diagnosis, driven by recent advancements in imaging technology that improve the accuracy of lesion targeting. Furthermore, the introduction of magnetic resonance imaging (MRI) fusion technology enhances the detection of clinically significant prostate cancer, allowing for more precise sampling. As awareness and screening programs for prostate cancer expand, the demand for prostate biopsy procedures will likely continue to rise, thus augmenting the growth of the biopsy guidance system market.

Lung Biopsy:

Lung biopsy is increasingly vital for diagnosing lung cancer, particularly given the high incidence rates of the disease. Techniques such as CT-guided lung biopsy allow for precise targeting of lung nodules that may be cancerous. As healthcare providers increasingly utilize advanced imaging techniques, the efficacy and accuracy of lung biopsies improve, leading to better patient outcomes. Additionally, the rise in lung cancer screening programs is expected to drive the need for lung biopsies, thus positively impacting the biopsy guidance system market. The growing acceptance of minimally invasive approaches will further popularize lung biopsy procedures.

Liver Biopsy:

Liver biopsy is crucial for diagnosing liver diseases, including cirrhosis and hepatocellular carcinoma. The prevalence of liver conditions has surged due to rising obesity rates and viral infections, leading to an increased demand for accurate diagnostic tools. Image-guided techniques, such as ultrasound-guided liver biopsy and CT-guided liver biopsy, have become essential for providing reliable diagnostic information. The minimally invasive nature of modern liver biopsy procedures encourages patient acceptance and adherence to follow-up care, further enhancing market growth in this segment. With continuous advancements in imaging technologies, liver biopsy techniques are expected to become more refined, resulting in improved patient outcomes.

Kidney Biopsy:

Kidney biopsy is a critical diagnostic tool for assessing renal conditions, including glomerulonephritis and renal tumors. As the prevalence of kidney disorders rises globally, driven by increasing diabetes and hypertension rates, the demand for kidney biopsy procedures is expected to grow. Techniques such as ultrasound-guided kidney biopsy enhance accuracy and safety, allowing for better patient experiences. Furthermore, ongoing research and advancements in imaging modalities will likely improve the efficacy of kidney biopsies, making them more appealing to both healthcare providers and patients. As awareness of kidney health continues to increase, the kidney biopsy segment is set to witness significant growth in the coming years.

By End User

Hospitals:

Hospitals constitute a significant end-user segment for biopsy guidance systems due to their advanced diagnostic capabilities and comprehensive patient care. In hospitals, biopsy procedures are performed by specialized healthcare professionals using state-of-the-art imaging technologies to ensure accurate targeting of lesions. The growing volume of cancer patients seeking diagnostic services is driving the demand for biopsy systems in hospitals. Additionally, hospitals often have the resources to implement advanced biopsy technologies, making them a preferred setting for complex biopsy procedures. The integration of multidisciplinary teams within hospitals also promotes collaborative approaches to patient management, further enhancing efficiency and outcomes.

Diagnostic Centers:

Diagnostic centers play a pivotal role in the biopsy guidance system market as they provide specialized services for diagnostic imaging and biopsy procedures. These centers are equipped with advanced imaging technologies that facilitate accurate and timely biopsies, catering to patients seeking outpatient services. As the demand for quick diagnostic services rises, diagnostic centers are increasingly adopting innovative biopsy technologies to enhance their service offerings. The convenience and accessibility of diagnostic centers, coupled with the rising incidence of various cancers, contribute to their growth in the biopsy guidance system market. Furthermore, partnerships with hospitals and oncologists allow diagnostic centers to broaden their patient base and improve service delivery.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are gaining prominence in the biopsy guidance system market as they provide a cost-effective alternative to traditional hospital settings. These centers offer outpatient surgical services, including various biopsy procedures, enabling patients to undergo diagnostics without the need for hospital admission. The growing preference for outpatient care, driven by advancements in minimally invasive techniques, is propelling the use of biopsy guidance systems in ASCs. Additionally, ASCs often have shorter wait times and lower costs, making them an attractive option for both patients and healthcare providers. The increasing acceptance of ASCs for cancer diagnostics is expected to contribute significantly to the growth of the biopsy guidance system market.

By Technology

MRI-guided Biopsy:

MRI-guided biopsy is an advanced technique that utilizes magnetic resonance imaging to provide high-resolution images of soft tissues, making it particularly effective for targeting lesions in organs such as the prostate and breast. This technology enhances the accuracy of biopsies by allowing clinicians to visualize abnormalities in real-time. The increasing adoption of MRI-guided biopsies is driven by their ability to improve diagnostic outcomes and reduce the need for repeat procedures. As MRI technology continues to advance, the integration of functional imaging capabilities will further enhance the diagnostic potential of this biopsy technique. Consequently, the market for MRI-guided biopsy systems is expected to see substantial growth in the coming years.

CT-guided Biopsy:

CT-guided biopsy employs computed tomography imaging to accurately locate and sample tissue from abnormal growths within the body. It is particularly useful in targeting deep-seated lesions that are difficult to access through conventional means. The growing prevalence of cancers, particularly lung cancer, is driving the demand for CT-guided biopsy procedures as they provide a reliable and minimally invasive diagnostic option. With advancements in CT imaging technology, the precision and safety profiles of these procedures continue to improve, making them more appealing to healthcare providers. As the awareness of the importance of early cancer detection grows, the adoption of CT-guided biopsy systems is expected to increase significantly.

Ultrasound-guided Biopsy:

Ultrasound-guided biopsy is a popular technique that utilizes real-time ultrasound imaging to guide biopsy needles to the target area. This method is particularly advantageous due to its non-invasive nature and the absence of ionizing radiation, making it a preferred choice for many clinicians. The rising incidence of conditions requiring biopsies, such as breast and liver diseases, is propelling the demand for ultrasound-guided biopsies. Furthermore, advancements in ultrasound technology, including the use of elastography and contrast agents, are enhancing the accuracy and efficacy of these procedures. The increasing emphasis on patient safety and comfort is expected to further drive the adoption of ultrasound-guided biopsy systems in clinical settings.

Stereotactic-guided Biopsy:

Stereotactic-guided biopsy techniques utilize advanced imaging systems to create a three-dimensional representation of the target area, enabling precise localization of lesions, particularly in the breast and brain. This technology is instrumental in ensuring accurate needle placement, resulting in higher diagnostic yield and reduced complications. As the focus on minimally invasive procedures intensifies, the stereotactic-guided biopsy segment is poised for significant growth. The continued development of sophisticated imaging systems and the integration of stereotactic techniques in routine clinical practice will enhance the appeal of this biopsy method. Consequently, the demand for stereotactic-guided biopsy systems is expected to increase as healthcare providers seek reliable and efficient diagnostic solutions.

PET-guided Biopsy:

Positron Emission Tomography (PET)-guided biopsy is an emerging technology that combines metabolic imaging with biopsy procedures. PET imaging allows for the visualization of metabolic activity in tissues, helping clinicians identify areas of concern that may not be detectable through conventional imaging techniques. As the understanding of cancer biology evolves, PET-guided biopsy is expected to become increasingly important for diagnosing and managing malignancies. The integration of PET technology into biopsy guidance systems enhances the precision of targeting cancerous lesions, allowing for better diagnostic outcomes. While still developing, the PET-guided biopsy segment holds significant promise for the future of cancer diagnostics, contributing to the overall growth of the biopsy guidance system market.

By Region

The North American region is currently the largest market for biopsy guidance systems, accounting for nearly 40% of the global market share in 2025. The dominance of North America can be attributed to the high prevalence of cancer, advanced healthcare infrastructure, and increased spending on healthcare. Moreover, the presence of leading medical technology companies and ongoing research initiatives focused on improving biopsy techniques are propelling market growth in this region. The CAGR for the North American biopsy guidance system market is expected to remain robust, reflecting the ongoing demand for innovative diagnostic solutions. As cancer screening programs become more widespread and patient awareness increases, the North American market is anticipated to maintain its leadership position through 2035.

In Europe, the biopsy guidance system market is also witnessing substantial growth, driven by increasing investments in healthcare technologies and the rising incidence of cancer across the region. Europe holds approximately 30% of the global market share, with a significant focus on early detection and diagnosis of cancer through advanced imaging modalities. Countries such as Germany, France, and the UK are leading the adoption of biopsy guidance systems, aided by supportive healthcare policies and reimbursement frameworks. The CAGR for the European market is projected to be around 6.5%, indicating ongoing progress in the adoption of innovative biopsy technologies. Additionally, the rise of outpatient services and diagnostic centers in Europe is expected to contribute to market growth, making it a key player in the global biopsy guidance system landscape.

Opportunities

The biopsy guidance system market is poised for multiple growth opportunities driven by technological advancements and increasing cancer awareness. One of the most notable opportunities lies in the development of hybrid imaging techniques that integrate multiple imaging modalities, such as combining MRI and PET, allowing for enhanced visualization and targeting of lesions. These advancements could lead to more precise biopsies and improved patient outcomes. Furthermore, as healthcare systems transition towards personalized medicine, the demand for accurate tissue characterization will rise, creating opportunities for novel biopsy technologies that provide comprehensive diagnostic information. The expansion of telemedicine and remote healthcare services also presents new avenues for the biopsy guidance system market, as patients can access specialized diagnostic services from the comfort of their homes, thus broadening the market's reach.

Another opportunity stems from the growing emphasis on preventative care and early cancer detection initiatives worldwide. Governments and healthcare organizations are increasingly investing in cancer screening programs, enhancing public awareness about the importance of early diagnosis. This trend is expected to lead to a surge in the number of biopsy procedures performed, as more cases are identified at early stages. Additionally, the rise in collaborations among medical technology companies, healthcare providers, and research institutions presents opportunities for innovation and the development of next-generation biopsy guidance systems. By leveraging these collaborations, companies can enhance their product offerings and meet the evolving needs of patients and healthcare providers alike.

Threats

Despite the promising growth trajectory of the biopsy guidance system market, several threats could hinder its progress. One significant challenge is the regulatory landscape surrounding medical devices, which can vary widely across different regions. Stringent regulations can lead to delays in product approvals and market entry, thereby affecting companies' ability to innovate and respond quickly to market demands. Additionally, the increasing cost of healthcare and the financial burden on patients may discourage individuals from seeking biopsies, particularly in regions where out-of-pocket expenses are high. Competitors in the biopsy guidance system market may also engage in price wars to gain market share, leading to reduced profit margins for manufacturers. Moreover, the ongoing debate around the necessity and frequency of biopsies in certain cancer screening contexts may impact the demand for biopsy guidance systems.

Another potential threat to the biopsy guidance system market is the emergence of alternative diagnostic methods that may reduce the reliance on invasive biopsy procedures. Techniques such as liquid biopsy, which analyzes circulating tumor DNA from blood samples, are gaining traction as less invasive alternatives for cancer detection and monitoring. If these methods prove to be as effective as traditional biopsies, they may shift the focus away from invasive procedures, leading to a decline in demand for biopsy guidance systems. Furthermore, the COVID-19 pandemic has underscored the importance of patient safety and may lead to long-term changes in how diagnostic procedures are conducted, potentially impacting the biopsy guidance system market.

Competitor Outlook

• BD (Becton, Dickinson and Company)
• Hitachi, Ltd.
• Fujifilm Holdings Corporation
• Siemens Healthineers
• Medtronic plc
• GE Healthcare
• Hologic, Inc.
• Canon Medical Systems Corporation
• Konica Minolta, Inc.
• Philips Healthcare
• Merit Medical Systems, Inc.
• Boston Scientific Corporation
• Varian Medical Systems, Inc.
• Neusoft Corporation
• Olympus Corporation

The competitive landscape of the biopsy guidance system market consists of a diverse range of companies, each striving to capture market share through innovation, quality, and technological advancements. Key players in this market are focusing on developing advanced imaging technologies and integrating them into biopsy systems to enhance accuracy and patient outcomes. Companies like BD and Hologic are well-known for their contributions to breast biopsy technologies, while giants like GE Healthcare and Siemens Healthineers are recognized for their cutting-edge imaging solutions that support various biopsy procedures. The landscape is characterized by strategic partnerships, collaborations, and acquisitions, as companies seek to leverage complementary strengths and enhance their product portfolios.

As the market grows, companies are also investing in research and development to introduce next-generation biopsy guidance systems that incorporate artificial intelligence and machine learning algorithms for improved diagnostic capabilities. For instance, Fujifilm and Olympus are exploring ways to incorporate AI-driven analytics in imaging systems to assist healthcare providers in making more informed decisions. Medtronic and Philips are also exploring opportunities in minimally invasive techniques, which are increasingly favored by patients and healthcare providers alike. As the competitive landscape evolves, companies that can effectively balance innovation with patient-centered solutions will likely emerge as leaders in the biopsy guidance system market.

Among the major players, Siemens Healthineers stands out with its extensive portfolio of imaging solutions and a strong focus on advancing biopsy techniques, particularly in the context of cancer diagnostics. The company has made significant investments in developing innovative technologies that enhance the precision of biopsy procedures. Hologic, a leader in women's health, has developed specialized systems for breast biopsies that incorporate the latest advancements in imaging technology and patient safety. Similarly, GE Healthcare has made strides in integrating advanced imaging with biopsy guidance systems, enhancing the overall accuracy and efficiency of the procedures. These leading companies are well-positioned to capitalize on the growing demand for biopsy guidance systems, ensuring they remain at the forefront of the market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GE Healthcare
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hitachi, Ltd.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Hologic, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Medtronic plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Philips Healthcare
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Neusoft Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Olympus Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Konica Minolta, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merit Medical Systems, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Varian Medical Systems, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boston Scientific Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Fujifilm Holdings Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Canon Medical Systems Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Biopsy Guidance System Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Ambulatory Surgical Centers
  • 6.2 Biopsy Guidance System Market, By Application
    • 6.2.1 Breast Biopsy
    • 6.2.2 Prostate Biopsy
    • 6.2.3 Lung Biopsy
    • 6.2.4 Liver Biopsy
    • 6.2.5 Kidney Biopsy
  • 6.3 Biopsy Guidance System Market, By Product Type
    • 6.3.1 Needle Biopsy
    • 6.3.2 Surgical Biopsy

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Biopsy Guidance System Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Biopsy Guidance System market is categorized based on

By Product Type

• Needle Biopsy
• Surgical Biopsy

By Application

• Breast Biopsy
• Prostate Biopsy
• Lung Biopsy
• Liver Biopsy
• Kidney Biopsy

By End User

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• BD (Becton, Dickinson and Company)
• Hitachi, Ltd.
• Fujifilm Holdings Corporation
• Siemens Healthineers
• Medtronic plc
• GE Healthcare
• Hologic, Inc.
• Canon Medical Systems Corporation
• Konica Minolta, Inc.
• Philips Healthcare
• Merit Medical Systems, Inc.
• Boston Scientific Corporation
• Varian Medical Systems, Inc.
• Neusoft Corporation
• Olympus Corporation